Xeris Biopharma Holdings, Inc. (XERS): Price-to-Sales Ratio

Xeris Biopharma revenue is based on the sales of Gvoke and Keveyis injection systems. The price-to-sales ratio visualizes the market valuation of these assets, where the parameter value equals 8.20. Diversification through new developments in neurology reduces risks. A stable cash flow from the endocrine portfolio confirms the business's operational resilience, ruling out any signs of waning demand.

XERS: Xeris Biopharma P/S Multiple 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for xerispharma.com (XERS)

- share price and consensus valuation forecast:

Price Performance Chart Xeris Biopharma Holdings, Inc.|XERS - Price Target Chart

- stock exchange capitalization data:

Market Valuation Xeris Pharma|XERS - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value of a Share Xeris Biopharma|XERS - Book Capitalization|Market Capitalization to Book Value Ratio xerispharma.com|XERS - Aggregate Company Assets

- debt obligations and liquidity statistics:

All Debt to Shareholders' Equity Ratio Xeris Biopharma|XERS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Xeris Biopharma|XERS - Company Aggregate Debts|Debts to Book Capitalization Xeris Biopharma Holdings|XERS - Company Long-Term Liabilities|Company Short-Term Indebtedness Xeris Biopharma|Immediate Liquidity xerispharma.com

- earnings and valuation multiples information:

XERS - Company Net Income|Expected Net Income Xeris Biopharma|XERS - P/E Multiple|Market Cap to Projected Earnings Xeris Pharma|XERS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Xeris Biopharma Holdings|XERS - Operating profit before deduction of amortization|Earnings per share for the trailing year Xeris Biopharma|XERS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months xerispharma.com|XERS - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Xeris Biopharma

- issuer revenue and sales details:

XERS - Company Revenue|Company Expected Sales Volume Xeris Biopharma Holdings, Inc.|XERS - Price-to-Revenue Ratio|Future Price to Revenue Xeris Pharma|XERS - Sales Growth YoY (TTM)

General company analysis:XERS Xeris Biopharma Inc

The market capitalization-to-revenue ratio determines the value of each unit of sales, allowing for the identification of asset overvaluation or hidden market imbalances through the analysis of actual transactions. By studying the P/S multiple dynamics, an investor assesses the premium the market assigns to the proprietary technologies of Xeris Biopharma (XERS), which create a defensive barrier against dumping by traditional pharma and confirm the fundamental resilience of the business.

Who Xeris Biopharma competes with

VRTX (Vertex Pharmaceuticals Incorporated) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc) - Price-to-Sales Ratio|United Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Pharmaceutical)|BBIO: P/S Multiple|BGM Group Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cogent Bio|KROS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio arcturusrx.com (ARCT)|Market Cap to Revenue Eton Pharmaceuticals ETON|P/S Multiple KMDA (kamada.com)|P/S Multiple Fulcrum Therapeutics, Inc. FULC|Abeona Therapeutics - P/S Multiple|mereobiopharma.com (MREO) - Market Cap to Revenue|Protalix BioTherapeutics Inc. (PLX) - Price-to-Revenue Ratio|PLRX (Pliant Therapeutics Inc) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Applied Therapeutics, Inc.|Rein Therapeutics Inc. (RNTX) - Price-to-Revenue Coefficient|Market Cap to Revenue GELS (Gelteq Limited)|P/S Multiple Aytu Therapeutics (AYTU)|Price-to-Revenue Ratio Chemomab Therapeutics Ltd. CMMB|Market Capitalization-to-Revenue Ratio SRXH|Polyrizon Limited - P/S Multiple|AEZS (zentaris.com) - Market Cap to Revenue Ratio|CYTH (Cyclo Therapeutics, Inc.) - Market Cap to Revenue|Price to Sales Inozyme Pharma, Inc. (INZY)|RPHM (Reneo Pharmaceuticals) - P/S Multiple|COSCIENS Biopharma (CSCI) - Price-to-Revenue Coefficient